Covaxin is a whole-virion inactivated Covid-19 investigational vaccine candidate that uses the same vero cell manufacturing platform that has been used in the production of polio vaccines for decades
The partnership is already underway having launched earlier last week, and the contract could be worth up to £211 million.
Fitch estimates JPL's EBITDA to drop significantly in FY23 due to lower volume and narrowing of the margin to 11% (FY22 estimate: 14%).
The focus should be on streamlining regulations, developing new molecules, increased industry academia collaboration and tapping the potential of traditional medicines
According to Fortune Business Insights, the launch of new PCR-based detection techniques will lead to a surge in demand for PCR instruments in the coming years
Nuvaxovid is the first protein-based Covid-19 vaccine authorized for use in Canada
AptarGroup acquired Voluntis and 80% of Weihai Hengyu Medical Products in 2021.
The speakers for the e-conference are: Dr. Mukund Chorgade, President/CSO, THINQ Pharma; Sudarshan Jain, Secretary General, Indian Pharmaceutical Alliance; Jayaseelan J., National Vice President (Industry Division), Indian Pharmaceutical Association; Spandan Mishra who is Director- Sales, Customer Service & Logistics for Evonik India, Nepal & Sri Lanka region; Dr. Kommu Nagaiah, Chief Scientist & Head, CSIR-IICT; Govind K. Jaju, Partner, Suingora Consulting; nd Pravin Prashant, Executive Editor, Indian Pharma Post & Editor, Indian Chemical News.
The construction is scheduled to begin in the third quarter of the calendar year 2022, with expected completion in early 2024
New subsidiaries to be established in Malaysia, Taiwan, Singapore, and Hong Kong
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
